Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent developments in the use of antiplatelet agents to prevent cardiovascular events.

Future cardiology - 1 May 2011

Lischke Stefan, Schneider David J

Abstract excerpt

Platelets are pivotal contributors to arterial thrombosis. Dual antiplatelet therapy with aspirin and clopidogrel has become the standard of care for the secondary prevention of cardiovascular events in patients with acute coronary syndromes and after percutaneous coronary intervention. Clinical evidence of the continued risk of cardiovascular events plus pharmacodynamic evidence of substantial variability in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aspirin
Share to ATP Binding Cassette Transporter, Subfamily B
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Fibrinolytic Agents

Share to Platelet Aggregation Inhibitors

Share to Secondary Prevention

Share to Ticlopidine

Source

Identifiers

PMID: 21627479
DOI: 10.2217/fca.11.8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent developments in the use of antiplatelet agents to prevent cardiovascular events.PMID 21627479Read ↗

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Semantic proximity Read ↗

Scientific and therapeutic advances in antiplatelet therapy.Semantic proximity Read ↗

Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?Semantic proximity Read ↗

Antiplatelet treatment for coronary heart diseaseSemantic proximity Read ↗

Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.Semantic proximity Read ↗

Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey.Semantic proximity Read ↗

Pharmacogenetics of the antiplatelet effect of aspirin.Semantic proximity Read ↗

High platelet reactivity and clinical outcome - fact and fiction.Semantic proximity Read ↗

Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms.Semantic proximity Read ↗

Aspirin and coronary artery disease.Semantic proximity Read ↗

Safety considerations with the use of platelet inhibitors for elderly patients with non-ST- elevation acute coronary syndrome.Semantic proximity Read ↗

Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. A systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.